

Etienne Garin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7858873/publications.pdf>

Version: 2024-02-01

94
papers

5,190
citations

108046

37
h-index

100535

70
g-index

95
all docs

95
docs citations

95
times ranked

4906
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective internal radiation therapy in older patients with hepatocellular carcinoma: a retrospective analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 417-421.	0.8	4
2	Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in France. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1-11.	0.9	3
3	TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1599-1607.	0.9	21
4	A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3340-3352.	3.3	30
5	Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 17-29.	3.7	307
6	Personalised dosimetry for SIRT: new standard or bridge to surgical resection? "Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 162.	3.7	2
7	Labeling of Hinokitiol with ⁹⁰ Y for Potential Radionuclide Therapy of Hepatocellular Carcinoma. <i>Processes</i> , 2021, 9, 940.	1.3	3
8	ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3794.	1.7	16
9	Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3897-3907.	0.8	59
10	Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas. <i>Current Oncology</i> , 2021, 28, 4530-4541.	0.9	1
11	Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2020, 6, 51.	3.4	176
12	Abscopal Effect After SIRT: It Exists, but How Could We Use It?. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1650-1651.	0.9	2
13	Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3729-3737.	0.7	56
14	Personalised Dosimetry in Radioembolisation for HCC: Impact on Clinical Outcome and on Trial Design. <i>Cancers</i> , 2020, 12, 1557.	1.7	40
15	Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with ⁹⁰ Y in the SARAH Study. <i>Radiology</i> , 2020, 296, 673-684.	3.6	117
16	Lymphocytes and Neutrophil-to-Lymphocyte Ratio Variations After Selective Internal Radiation Treatment for HCC: A Retrospective Cohort Study. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1175-1181.	0.9	12
17	Streamlining TARE or personalizing SIRT? Different philosophies to treat different HCCs with Yttrium-90. <i>Journal of Hepatology</i> , 2020, 72, 1046-1048.	1.8	4
18	Major impact of personalized dosimetry using ⁹⁰ Y loaded glass microspheres SIRT in HCC: Final overall survival analysis of a multicenter randomized phase II study (DOSISPHERE-01).. <i>Journal of Clinical Oncology</i> , 2020, 38, 516-516.	0.8	22

#	ARTICLE	IF	CITATIONS
19	Incidental anal ¹⁸ F-fluorodeoxyglucose uptake: Should we further examine the patient?. World Journal of Clinical Cases, 2020, 8, 3679-3690.	0.3	1
20	Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives. Frontiers in Medicine, 2019, 6, 132.	1.2	96
21	Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1695-1704.	3.3	104
22	⁹⁰ Y-Loaded Microsphere SIRT of HCC Patients With Portal Vein Thrombosis: High Clinical Impact of ^{99m} Tc-MAA SPECT/CT-Based Dosimetry. Seminars in Nuclear Medicine, 2019, 49, 218-226.	2.5	30
23	Comparison of ¹⁸ F-Choline PET/CT and MRI functional parameters in prostate cancer. Annals of Nuclear Medicine, 2019, 33, 47-54.	1.2	0
24	Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 669-676.	3.3	44
25	Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with ¹⁸⁸ Re-SSS Lipiodol radioembolization. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1506-1517.	3.3	15
26	Comparison of choline influx from dynamic ¹⁸ F-Choline PET/CT and clinicopathological parameters in prostate cancer initial assessment. Annals of Nuclear Medicine, 2018, 32, 281-287.	1.2	9
27	Negative phase 3 study of ⁹⁰ Y microspheres versus sorafenib in HCC. Lancet Oncology, The, 2018, 19, e70.	5.1	16
28	Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 392-401.	3.3	58
29	A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and ⁹⁰ Y-loaded glass microsphere selective internal radiation therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1731-1741.	3.3	25
30	Optimization of temporal sampling for ¹⁸ F-choline uptake quantification in prostate cancer assessment. EJNMMI Research, 2018, 8, 49.	1.1	3
31	Is there a place for nuclear medicine in the radioembolization of liver tumors?. Medecine Nucleaire, 2017, 41, 21-26.	0.2	2
32	Does ⁹⁰ Y Radioembolization Prolong Overall Survival Compared With Chemoembolization in Patients With Hepatocellular Carcinoma?. Gastroenterology, 2017, 152, 1624-1625.	0.6	1
33	Consolidation anti-CD22 fractionated radioimmunotherapy with ⁹⁰ Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. Lancet Haematology, the, 2017, 4, e35-e45.	2.2	33
34	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncology, The, 2017, 18, 1624-1636.	5.1	595
35	¹⁸ F-Choline Uptake in Acute Ischemic Stroke. Clinical Nuclear Medicine, 2017, 42, e121-e122.	0.7	5
36	High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with ⁹⁰ Y-loaded glass microsphere radioembolization. Liver International, 2017, 37, 101-110.	1.9	71

#	ARTICLE	IF	CITATIONS
37	Incidental colorectal focal 18F-FDG uptake: a novel indication for colonoscopy. <i>Endoscopy International Open</i> , 2017, 05, E924-E930.	0.9	7
38	High Impact of Preferential Flow on ^{99m} Tc-MAA and ⁹⁰ Y-Loaded Microsphere Uptake Correlation. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1829-1830.	2.8	7
39	Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer. <i>Radiotherapy and Oncology</i> , 2016, 120, 512-518.	0.3	38
40	Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT). <i>European Journal of Radiology</i> , 2016, 85, 1445-1452.	1.2	23
41	Occupational radiation exposure of medical staff performing ⁹⁰ Y-loaded microsphere radioembolization. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 824-831.	3.3	15
42	Clinical impact of ^{99m} Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with ⁹⁰ Y-loaded microspheres. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 559-575.	3.3	121
43	Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 635-643.	3.3	74
44	Glass Microspheres ⁹⁰ Y Selective Internal Radiation Therapy and Chemotherapy as First-Line Treatment of Intrahepatic Cholangiocarcinoma. <i>Clinical Nuclear Medicine</i> , 2015, 40, 851-855.	0.7	53
45	Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1874-1878.e2.	0.2	5
46	Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2015, 4, 16-25.	4.2	40
47	Intra-arterial Yttrium-90 Radioembolization Combined with Systemic Chemotherapy is a Promising Method for Downstaging Unresectable Huge Intrahepatic Cholangiocarcinoma to Surgical Treatment. <i>Annals of Surgical Oncology</i> , 2015, 22, 3102-3108.	0.7	111
48	Radioembolization with ⁹⁰ Y-loaded microspheres: high clinical impact of treatment simulation with MAA-based dosimetry. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1189-1191.	3.3	8
49	Personalized Dosimetry with Intensification Using ⁹⁰ Y-Loaded Glass Microsphere Radioembolization Induces Prolonged Overall Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis. <i>Journal of Nuclear Medicine</i> , 2015, 56, 339-346.	2.8	122
50	Sorafenib or ⁹⁰ Y-loaded resin microsphere radioembolization for locally advanced hepatocellular carcinoma, what should we trust?. <i>Liver International</i> , 2015, 35, 1779-1780.	1.9	0
51	Reply: Modifying the Poor Prognosis Associated with ¹⁸ F-FDG Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT). <i>Journal of Nuclear Medicine</i> , 2015, 56, 969-969.	2.8	1
52	^{99m} Tc-MAA Based Dosimetry for Liver Cancer Treated Using ⁹⁰ Y-Loaded Microspheres: Known Proof of Effectiveness. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1391-1392.	2.8	7
53	High Prognostic Value of ¹⁸ F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1786-1790.	2.8	153
54	Pretreatment Dosimetry in HCC Radioembolization with ⁹⁰ Y Glass Microspheres Cannot Be Invalidated with a Bare Visual Evaluation of ^{99m} Tc-MAA Uptake of Colorectal Metastases Treated with Resin Microspheres. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1215-1216.	2.8	16

#	ARTICLE	IF	CITATIONS
55	Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT. EJNMMI Research, 2013, 3, 11.	1.1	67
56	Volumetric Changes after 90Y Radioembolization for Hepatocellular Carcinoma in Cirrhosis: An Option to Portal Vein Embolization in a Preoperative Setting?. Annals of Surgical Oncology, 2013, 20, 2518-2525.	0.7	76
57	Pre-therapeutic dosimetry evaluation and selective internal radiation therapy of hepatocellular carcinoma using yttrium-90-loaded microspheres. Journal of Hepatology, 2013, 58, 1055-1056.	1.8	6
58	Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1057-1068.	3.3	172
59	In vitro demonstration of synergy/additivity between (188)rhenium and sorafenib on hepatoma lines: preliminary results. Anticancer Research, 2013, 33, 3871-7.	0.5	3
60	-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside. International Journal of Molecular Imaging, 2012, 2012, 1-9.	1.3	21
61	Optimization of Hepatocarcinoma Uptake with Radiolabeled Lipiodol: Development of New Lipiodol Formulations with Increased Viscosity. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 149-155.	0.7	15
62	Reduction of β^2 -radiation exposure during preparation of 188Re-labelled Lipiodol for hepatocellular carcinoma treatment. Nuclear Medicine Communications, 2012, 33, 205-208.	0.5	6
63	Dosimetry Based on ^{99m}Tc -Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with ^{90}Y -Loaded Glass Microspheres: Preliminary Results. Journal of Nuclear Medicine, 2012, 53, 255-263.	2.8	242
64	Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 872-880.	3.3	40
65	Research Reporting Standards for Radioembolization of Hepatic Malignancies. Journal of Vascular and Interventional Radiology, 2011, 22, 265-278.	0.2	185
66	Clinical Feasibility of Fast 3-Dimensional Dosimetry of the Liver for Treatment Planning of Hepatocellular Carcinoma with ^{90}Y -Microspheres. Journal of Nuclear Medicine, 2011, 52, 1930-1937.	2.8	61
67	Lipid Nanocapsules Loaded with Rhenium-188 Reduce Tumor Progression in a Rat Hepatocellular Carcinoma Model. PLoS ONE, 2011, 6, e16926.	1.1	38
68	Effectiveness of quantitative MAA SPECT/CT for the definition of vascularized hepatic volume and dosimetric approach. Nuclear Medicine Communications, 2011, 32, 1245-1255.	0.5	29
69	Radioembolisation of hepatocellular carcinoma patients using 90Y-labelled microspheres: towards a diffusion of the technique?. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2114-2116.	3.3	3
70	Meta-analysis of interstitial pneumonia in studies evaluating iodine-131-labeled lipiodol for hepatocellular carcinoma using exact likelihood approach. Pharmacoepidemiology and Drug Safety, 2011, 20, 956-963.	0.9	8
71	Automation of labelling of Lipiodol with high-activity generator-produced 188Re. Applied Radiation and Isotopes, 2011, 69, 426-430.	0.7	23
72	Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. Journal of Clinical Oncology, 2011, 29, 3194-3200.	0.8	176

#	ARTICLE	IF	CITATIONS
73	131 I-Labeled Lipiodol-Induced Interstitial Pneumonia. <i>Chest</i> , 2011, 139, 1463-1469.	0.4	19
74	Utility of Quantitative ^{99m} Tc-MAA SPECT/CT for ⁹⁰ yttrium-Labelled Microsphere Treatment Planning: Calculating Vascularized Hepatic Volume and Dosimetric Approach. <i>International Journal of Molecular Imaging</i> , 2011, 2011, 1-8.	1.3	28
75	First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 453-461.	3.3	38
76	Subthalamic nucleus stimulation affects limbic and associative circuits: a PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1512-1520.	3.3	58
77	Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2307-2314.	3.3	121
78	Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 41-49.	8.2	47
79	Decrease of Prefrontal Metabolism After Subthalamic Stimulation in Obsessive-Compulsive Disorder: A Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2010, 68, 1016-1022.	0.7	111
80	Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen. <i>Nuclear Medicine and Biology</i> , 2010, 37, 777-784.	0.3	14
81	Predictive Value of ¹⁸ F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2009, 50, 858-864.	2.8	224
82	Adjuvant Intraarterial Injection of ¹³¹ I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up. <i>Journal of Nuclear Medicine</i> , 2008, 49, 362-366.	2.8	26
83	Dosimetric evaluation and therapeutic response to internal radiation therapy of hepatocarcinomas using iodine-131-labelled lipiodol. <i>Nuclear Medicine Communications</i> , 2008, 29, 815-825.	0.5	24
84	Radioisotopic Location of the Sentinel Node in Vaginal Mucous Melanoma Before Laparoscopic Sampling. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2008, 18, 195-196.	0.4	5
85	18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease. <i>Haematologica</i> , 2008, 93, 128-131.	1.7	28
86	Impact of PET-FDG in the Diagnosis and Therapeutic Care of Patients Presenting with Metastases of Unknown Primary. <i>Cancer Investigation</i> , 2007, 25, 232-239.	0.6	10
87	Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2007, 82, 76-82.	0.3	41
88	Association of cisplatin and intra-arterial injection of 131I-lipiodol in treatment of hepatocellular carcinoma: Results of phase II trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 745-750.	0.4	16
89	^{99m} Tc/ ¹⁸⁸ Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: formulation and biodistribution. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 602-607.	3.3	66
90	Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2006, 24, 5366-5372.	0.8	290

#	ARTICLE	IF	CITATIONS
91	Effect of Stabilized Iodized Oil Emulsion on Experimentally Induced Hepatocellular Carcinoma in Rats. Journal of Vascular and Interventional Radiology, 2005, 16, 841-848.	0.2	6
92	A kit formulation for the labelling of lipiodol with generator-produced ¹⁸⁸ Re. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 857-867.	0.5	15
93	¹⁸⁸ Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma. Nuclear Medicine Communications, 2004, 25, 1007-1013.	0.5	31
94	Development of ^{99m} Tc labelled Lipiodol: biodistribution following injection into the hepatic artery of the healthy pig. Nuclear Medicine Communications, 2004, 25, 291-297.	0.5	14